LAVA Therapeutics (NASDAQ:LVTX) Sees Large Growth in Short Interest

LAVA Therapeutics (NASDAQ:LVTX) was the target of a large growth in short interest in December. As of December 15th, there was short interest totalling 58,700 shares, a growth of 178.2% from the November 30th total of 21,100 shares. Based on an average daily volume of 89,100 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.4% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

LVTX has been the subject of a number of research reports. Leerink Partners reiterated a “market perform” rating and set a $2.00 target price (down previously from $11.00) on shares of LAVA Therapeutics in a research report on Thursday, December 12th. JMP Securities restated a “market perform” rating and set a $6.00 target price on shares of LAVA Therapeutics in a research report on Wednesday, December 11th. Citizens Jmp downgraded shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Leerink Partnrs cut shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, HC Wainwright lowered their price objective on shares of LAVA Therapeutics from $6.00 to $2.00 and set a “buy” rating for the company in a research report on Friday, December 20th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $3.33.

LAVA Therapeutics Trading Up 0.1 %

NASDAQ LVTX traded up $0.00 during mid-day trading on Friday, hitting $0.99. The company’s stock had a trading volume of 253,037 shares, compared to its average volume of 515,669. The firm has a market capitalization of $25.18 million, a price-to-earnings ratio of -0.96 and a beta of 0.43. LAVA Therapeutics has a twelve month low of $0.88 and a twelve month high of $6.47. The company’s 50 day simple moving average is $1.56 and its 200 day simple moving average is $1.73.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of LVTX. Virtu Financial LLC purchased a new stake in shares of LAVA Therapeutics during the third quarter worth $32,000. XTX Topco Ltd purchased a new stake in LAVA Therapeutics in the second quarter valued at approximately $55,000. Finally, Pathway Financial Advisors LLC lifted its position in LAVA Therapeutics by 70.8% during the third quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock valued at $170,000 after purchasing an additional 42,500 shares during the last quarter.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.